{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T09:32:20Z","timestamp":1787045540449,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01540-9","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T09:07:46Z","timestamp":1787044066000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["FOLFOX in Esophageal Squamous Cell Carcinoma: Current Evidence and Future Role as a Cisplatin-Sparing Chemoimmunotherapy Backbone"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-4795","authenticated-orcid":false,"given":"Tamotsu","family":"Sagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshi","family":"Fujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"issue":"3","key":"1540_CR1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10388-023-00993-2","volume":"20","author":"Y Kitagawa","year":"2023","unstructured":"Kitagawa Y, Ishihara R, Ishikawa H, Ito Y, Oyama T, Oyama T, et al. Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal Society: part 1. Esophagus. 2023;20(3):343\u201372. https:\/\/doi.org\/10.1007\/s10388-023-00993-2.","journal-title":"Esophagus"},{"issue":"3","key":"1540_CR2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s10388-023-00994-1","volume":"20","author":"Y Kitagawa","year":"2023","unstructured":"Kitagawa Y, Ishihara R, Ishikawa H, Ito Y, Oyama T, Oyama T, et al. Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal Society: part 2. Esophagus. 2023;20(3):373\u201389. https:\/\/doi.org\/10.1007\/s10388-023-00994-1.","journal-title":"Esophagus"},{"issue":"1","key":"1540_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1245\/s10434-011-2049-9","volume":"19","author":"N Ando","year":"2012","unstructured":"Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19(1):68\u201374. https:\/\/doi.org\/10.1245\/s10434-011-2049-9.","journal-title":"Ann Surg Oncol"},{"issue":"10447","key":"1540_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0140-6736(24)00745-1","volume":"404","author":"K Kato","year":"2024","unstructured":"Kato K, Machida R, Ito Y, Daiko H, Ozawa S, Ogata T, et al. Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial. Lancet. 2024;404(10447):55\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(24)00745-1.","journal-title":"Lancet"},{"issue":"17","key":"1540_CR5","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1001\/jama.281.17.1623","volume":"281","author":"JS Cooper","year":"1999","unstructured":"Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85\u2009\u2013\u200901). JAMA. 1999;281(17):1623\u20137. https:\/\/doi.org\/10.1001\/jama.281.17.1623.","journal-title":"JAMA"},{"issue":"5","key":"1540_CR6","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1200\/JCO.20.5.1167","volume":"20","author":"BD Minsky","year":"2002","unstructured":"Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, et al. INT 0123 (Radiation Therapy Oncology Group 94\u2009\u2013\u200905) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20(5):1167\u201374. https:\/\/doi.org\/10.1200\/JCO.20.5.1167.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1540_CR7","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386(5):449\u201362. https:\/\/doi.org\/10.1056\/NEJMoa2111380.","journal-title":"N Engl J Med"},{"issue":"9","key":"1540_CR8","doi-asserted-by":"publisher","first-page":"e7235","DOI":"10.1002\/cam4.7235","volume":"13","author":"K Kato","year":"2024","unstructured":"Kato K, Doki Y, Chau I, Xu J, Wyrwicz L, Motoyama S, et al. Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial. Cancer Med. 2024;13(9):e7235. https:\/\/doi.org\/10.1002\/cam4.7235.","journal-title":"Cancer Med"},{"issue":"2","key":"1540_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10388-022-00970-1","volume":"20","author":"K Kato","year":"2023","unstructured":"Kato K, Doki Y, Ogata T, Hara H, Kojima T, Abe T, et al. First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648\/ONO-4538-50). Esophagus. 2023;20(2):291\u2013301. https:\/\/doi.org\/10.1007\/s10388-022-00970-1.","journal-title":"Esophagus"},{"issue":"10302","key":"1540_CR10","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(21)01234-4.","journal-title":"Lancet"},{"issue":"5","key":"1540_CR11","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","volume":"24","author":"J Xu","year":"2023","unstructured":"Xu J, Kato K, Raymond E, Hubner RA, Shu Y, Pan Y, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2023;24(5):483\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(23)00108-0.","journal-title":"Lancet Oncol"},{"key":"1540_CR12","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ejca.2017.07.038","volume":"84","author":"C Bascoul-Mollevi","year":"2017","unstructured":"Bascoul-Mollevi C, Gourgou S, Galais MP, Raoul JL, Bouche O, Douillard JY, et al. Health-related quality of life results from the PRODIGE 5\/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer. Eur J Cancer. 2017;84:239\u201349. https:\/\/doi.org\/10.1016\/j.ejca.2017.07.038.","journal-title":"Eur J Cancer"},{"issue":"4","key":"1540_CR13","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/onc.2009.356","volume":"29","author":"A Tesniere","year":"2010","unstructured":"Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010;29(4):482\u201391. https:\/\/doi.org\/10.1038\/onc.2009.356.","journal-title":"Oncogene"},{"issue":"14","key":"1540_CR14","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1111\/febs.70102","volume":"292","author":"S Zhao","year":"2025","unstructured":"Zhao S, Sun D, Yu H, Wang M, Xu B, Wang Y, et al. Oxaliplatin accelerates immunogenic cell death by activating the cGAS\/STING\/TBK1\/IRF5 pathway in gastric cancer. FEBS J. 2025;292(14):3814\u201328. https:\/\/doi.org\/10.1111\/febs.70102.","journal-title":"FEBS J"},{"issue":"8","key":"1540_CR15","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/annonc\/mdi249","volume":"16","author":"AM Mauer","year":"2005","unstructured":"Mauer AM, Kraut EH, Krauss SA, Ansari RH, Kasza K, Szeto L, et al. Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol. 2005;16(8):1320\u20135. https:\/\/doi.org\/10.1093\/annonc\/mdi249.","journal-title":"Ann Oncol"},{"issue":"3","key":"1540_CR16","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S1470-2045(14)70028-2","volume":"15","author":"T Conroy","year":"2014","unstructured":"Conroy T, Galais MP, Raoul JL, Bouche O, Gourgou-Bourgade S, Douillard JY, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5\/ACCORD17): final results of a randomised, phase 2\/3 trial. Lancet Oncol. 2014;15(3):305\u201314. https:\/\/doi.org\/10.1016\/S1470-2045(14)70028-2.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1540_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10388-022-00951-4","volume":"20","author":"T Kadono","year":"2023","unstructured":"Kadono T, Yamamoto S, Hirose T, Honma Y, Shoji H, Iwasa S, et al. Safety and short-term efficacy of preoperative FOLFOX therapy in patients with resectable esophageal squamous cell carcinoma who are ineligible for cisplatin. Esophagus. 2023;20(1):109\u201315. https:\/\/doi.org\/10.1007\/s10388-022-00951-4.","journal-title":"Esophagus"},{"issue":"2","key":"1540_CR18","doi-asserted-by":"publisher","first-page":"761","DOI":"10.21873\/invivo.13499","volume":"38","author":"M Yada","year":"2024","unstructured":"Yada M, Yamamoto S, Honma Y, Hirano H, Okita N, Shoji H, et al. Retrospective analysis of definitive chemoradiotherapy with FOLFOX in patients with esophageal cancer intolerant to cisplatin. Vivo. 2024;38(2):761\u20136. https:\/\/doi.org\/10.21873\/invivo.13499.","journal-title":"Vivo"},{"issue":"1","key":"1540_CR19","doi-asserted-by":"publisher","first-page":"8031","DOI":"10.1038\/s41598-025-92657-7","volume":"15","author":"K Shiraishi","year":"2025","unstructured":"Shiraishi K, Okada M, Yamamoto S, Matsubara Y, Masuishi T, Shimozaki K, et al. The efficacy and safety of FOLFOX therapy for advanced esophageal squamous cell carcinoma. Sci Rep. 2025;15(1):8031. https:\/\/doi.org\/10.1038\/s41598-025-92657-7.","journal-title":"Sci Rep"},{"issue":"2suppl","key":"1540_CR20","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1200\/JCO.2026.44.2_suppl.388","volume":"44","author":"N Ogura","year":"2026","unstructured":"Ogura N, Yamamoto S, Morita R, Imazeki H, Yokoyama K, Honma Y, et al. Comparison between nivolumab plus ipilimumab, FOLFOX and nivolumab plus FOLFOX therapy as first-line treatment for cisplatin-unfit advanced esophageal squamous cell carcinoma. J Clin Oncol. 2026;44(2suppl):388. https:\/\/doi.org\/10.1200\/JCO.2026.44.2_suppl.388.","journal-title":"J Clin Oncol"},{"key":"1540_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s10388-026-01227-x","author":"N Ogura","year":"2026","unstructured":"Ogura N, Yamamoto S, Morita R, Imazeki H, Takahashi H, Honma Y, et al. FOLFOX plus nivolumab combination therapy for cisplatin-unfit patients with untreated advanced esophageal squamous cell carcinoma. Esophagus. 2026. https:\/\/doi.org\/10.1007\/s10388-026-01227-x.","journal-title":"Esophagus"},{"key":"1540_CR22","doi-asserted-by":"publisher","first-page":"S196","DOI":"10.1016\/j.annonc.2024.05.405","volume":"35","author":"Y Kubota","year":"2024","unstructured":"Kubota Y, Ueyama S, Yamamoto Y, Amanuma Y, Inagaki C, Matoba R, et al. A phase II study of mFOLFOX6 plus nivolumab as initial therapy for patients with advanced esophageal squamous-cell cancer: FLONTALE trial. Ann Oncol. 2024;35:S196. https:\/\/doi.org\/10.1016\/j.annonc.2024.05.405.","journal-title":"Ann Oncol"},{"key":"1540_CR23","unstructured":"Japan Registry of Clinical Trials. jRCTs051240108. Phase II trial of mFOLFOX6 plus nivolumab as first-line treatment for unresectable advanced or recurrent esophageal cancer (OXA-REPLACE trial). Available from: https:\/\/jrct.mhlw.go.jp\/latest-detail\/jRCTs051240108. Accessed June 18, 2026."},{"key":"1540_CR24","doi-asserted-by":"publisher","first-page":"100171","DOI":"10.1016\/j.esmogo.2025.100171","volume":"8","author":"M Tamba","year":"2025","unstructured":"Tamba M, Chin K, Osumi H, Ogura M, Fukuoka S, Udagawa S, et al. Real-world clinical impact of first-line immune checkpoint inhibitor-based therapy in advanced esophageal squamous cell carcinoma. ESMO Gastrointest Oncol. 2025;8:100171. https:\/\/doi.org\/10.1016\/j.esmogo.2025.100171.","journal-title":"ESMO Gastrointest Oncol"},{"issue":"16","key":"1540_CR25","doi-asserted-by":"publisher","first-page":"4806","DOI":"10.3390\/jcm13164806","volume":"13","author":"Y Nakayama","year":"2024","unstructured":"Nakayama Y, Ando T, Takagi H, Motoo I, Ueda Y, Sakumura M, et al. Efficacy and safety of immune checkpoint inhibitor combination therapy for dysphagia in patients with advanced esophageal cancer. J Clin Med. 2024;13(16):4806. https:\/\/doi.org\/10.3390\/jcm13164806.","journal-title":"J Clin Med"},{"issue":"6","key":"1540_CR26","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s00280-008-0834-3","volume":"63","author":"V Chiarion-Sileni","year":"2009","unstructured":"Chiarion-Sileni V, Innocente R, Cavina R, Cetto GL, Mione CA, Uzzau A, et al. Multi-center phase II trial of chemo-radiotherapy with 5-fluorouracil, leucovorin and oxaliplatin in locally advanced esophageal cancer. Cancer Chemother Pharmacol. 2009;63(6):1111\u20139. https:\/\/doi.org\/10.1007\/s00280-008-0834-3.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"1540_CR27","doi-asserted-by":"publisher","first-page":"816","DOI":"10.4143\/crt.2016.417","volume":"49","author":"SH Lim","year":"2017","unstructured":"Lim SH, Shim YM, Park SH, Kim HK, Choi YS, Ahn MJ, et al. A randomized phase II study of leucovorin\/5-fluorouracil with or without oxaliplatin (LV5FU2 vs. FOLFOX) for curatively resected, node-positive esophageal squamous cell carcinoma. Cancer Res Treat. 2017;49(3):816\u201323. https:\/\/doi.org\/10.4143\/crt.2016.417.","journal-title":"Cancer Res Treat"},{"issue":"11","key":"1540_CR28","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","volume":"20","author":"K Kato","year":"2019","unstructured":"Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(11):1506\u201317. https:\/\/doi.org\/10.1016\/S1470-2045(19)30626-6.","journal-title":"Lancet Oncol"},{"key":"1540_CR29","doi-asserted-by":"publisher","unstructured":"Shah MA, Kennedy EB, Deighton D, Jhawer M, Kadakia KC, Mukherjee S et al. Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline update. J Clin Oncol 2026 Feb 26:JCO2502958. https:\/\/doi.org\/10.1200\/JCO-25-02958","DOI":"10.1200\/JCO-25-02958"},{"issue":"2","key":"1540_CR30","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s10388-022-00968-9","volume":"20","author":"T Ura","year":"2023","unstructured":"Ura T, Hironaka S, Tsubosa Y, Mizusawa J, Kato K, Tsushima T, et al. Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807. Esophagus. 2023;20(2):272\u201380. https:\/\/doi.org\/10.1007\/s10388-022-00968-9.","journal-title":"Esophagus"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01540-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01540-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01540-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T09:07:47Z","timestamp":1787044067000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01540-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1540"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01540-9","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"assertion":[{"value":"3 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"193"}}